A carregar...
Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent
Under an NIH priority to identify new drugs to treat class B parasitic agents, we performed high-throughput screens, which identified the activity of auranofin (Ridaura) against Entamoeba histolytica and Giardia intestinalis, major causes of water- and foodborne outbreaks. Auranofin, an orally admin...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5192119/ https://ncbi.nlm.nih.gov/pubmed/27821451 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01947-16 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|